Sunshine Biopharma (OTCMKTS:SBFM) has just filed a patent application for a potential new treatment for neurodegenerative disorders. It includes experimental results that show certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells. It is a process that mimics neuronal degeneration.
Neurodegeneration happens when there is progressive loss of neuronal function – it could eventually result in cell death. Amyotrophic lateral sclerosis (ALS), Parkinson’s disease, multiple sclerosis, Alzheimer’s disease, and Huntington’s disease, come under the category of neurodegenerative diseases. Till date, there is no known technique to reverse progressive degeneration of neurons, so these diseases are considered to be incurable. They affect millions of people worldwide. As per the CDC, as many as 5.8 million Americans were living with Alzheimer’s disease in 2020! Moreover, around 1.2 million people might have Parkinson’s disease in the US by 2030.
Recent biochemical research studies have shown there are numerous underlying similarities among these diseases at the sub-cellular level. They suggest that adopting a given therapeutic approach for one neurodegenerative disease might ameliorate other diseases in the class.
Dr. Steve Slilaty, CEO of Sunshine Biopharma is hopeful about the recent findings of their ongoing mRNA-as-therapeutic-agents research. This treatment could stop progression of neurodegeneration, ease symptoms, relieve pain, and improve mobility.
